← All organizations
Highest phase reached
Phase 3
First clinical trial
Jan 1, 2008Last known activity
Oct 31, 2021
Acquired by Merck on Sep 30, 2021
Timeline
2000s
- Jan 1, 2004
Acceleron Pharma, Inc.— Founded
2020s
- Sep 30, 2021
Merck— Acquired By
Drugs by trial phase (10 distinct, 33 trials)
Phase 3 (3 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Indications
Studied for
- Anemia
- Atrophy
- beta-Thalassemia
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Charcot-Marie-Tooth Disease
- Familial Primary Pulmonary Hypertension
- Hereditary Sensory and Motor Neuropathy
- Hypertension
- Kidney Diseases
- Kidney Failure, Chronic
- Multiple Myeloma
- Muscular Atrophy
- Muscular Dystrophies
- Muscular Dystrophy, Duchenne
- Muscular Dystrophy, Facioscapulohumeral
- Musculoskeletal Diseases
- Myelodysplastic Syndromes
- Neoplasms, Plasma Cell
- Nerve Compression Syndromes
- Osteoporosis
- Preleukemia
- Squamous Cell Carcinoma of Head and Neck
- Syndrome
- Thalassemia
- Tooth Diseases
Recent trials (42)
- NCT04945460Study directorPhase 2Oct 31, 2021
- NCT04945460Lead sponsorPhase 2Oct 31, 2021
- NCT04896008Study directorPhase 3Oct 13, 2021
- NCT04896008Lead sponsorPhase 3Oct 13, 2021
- NCT04948554Study directorPhase 1/Phase 2Sep 16, 2021
- NCT04948554Lead sponsorPhase 1/Phase 2Sep 16, 2021
- NCT04811092Study directorPhase 3Jul 28, 2021
- NCT04811092Lead sponsorPhase 3Jul 28, 2021
- NCT04796337Lead sponsorPhase 3May 12, 2021
- NCT04796337Study directorPhase 3May 12, 2021
- NCT04576988Lead sponsorPhase 3Dec 31, 2020
- NCT04576988Study directorPhase 3Dec 31, 2020
- NCT04143724CollaboratorPhase 2Nov 1, 2019
- NCT03943290Lead sponsorPhase 2May 10, 2019
- NCT03738150Study directorPhase 2May 1, 2019
Details
- Founded
- Boston, Massachusetts, US Jan 1, 2004
- Last known activity
- Oct 31, 2021